• EMVision to raise $12.0 million via Placement
• Funds will advance emuTM and First Responder programs
• Launch of Share Purchase Plan for Eligible Shareholders

EMVision Medical Devices Limited (ASX:EMV) has received firm, binding commitments from institutional, sophisticated and professional investors for $12.0 million (before costs) under a placement of fully paid ordinary shares at an issue price of $1.94 per share, together with free attaching options. The funds raised will enable the company to advance through major milestones for the emuTM (in-hospital) and First Responder (pre-hospital) programs over FY26 and FY27. EMVision is also offering a Share Purchase Plan to Eligible Shareholders to raise up to $1 million (before costs), with the ability to accept oversubscriptions capped at a total of $2 million (before costs). Participants in the SPP will also receive free attaching options on the same terms as the Placement Attaching Options. The company's CEO and MD, Scott Kirkland, said the funds raised will allow EMVision to progress its clinical, regulatory and go-to-market activities, while maintaining a strong balance sheet as it advances towards market access and commercialisation.

The funds raised will enable the Company to advance through major milestones for the emuTM (in-hospital) and First Responder (pre-hospital) programs over FY26 and FY27. EMVision is well funded to execute on its clinical, regulatory and market access program.